Patient-reported Itch Outcome Measures for Chronic Pruritus in Dystrophic Epidermolysis Bullosa: Exploratory Analysis of a Phase 2 Randomized Controlled Trial
DOI:
https://doi.org/10.2340/actadv.v106.adv-2025-0139Keywords:
chronic itch, itch numerical rating scale, Itch Severity Item, ItchyQol, health-related quality of life, quality of life questionnaires, dystrophic epidermolysis bullosaDownloads
References
de Vere Hunt I, Halley M, Sum K, Yekrang K, Phung M, Good J, et al. A qualitative exploration of the experiences of itch for adults living with epidermolysis bullosa. Br J Dermatol 2022; 187: 261–263. DOI: https://doi.org/10.1111/bjd.21031
Danial C, Adeduntan R, Gorell ES, Lucky AW, Paller AS, Bruckner A, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol 2015; 32: 53–59. DOI: https://doi.org/10.1111/pde.12391
Korte EWH, Welponer T, Kottner J, van der Werf S, van den Akker PC, Horváth B, et al. Heterogeneity of reported outcomes in epidermolysis bullosa clinical research: A scoping review as a first step towards outcome harmonization. Br J Dermatol 2023; 189: 80–90. DOI: https://doi.org/10.1093/bjd/ljad077
Silverberg JI, Lai JS, Kantor RW, Dalal P, Hickey C, Shaunfield S, et al. Development, validation, and interpretation of the PROMIS Itch Questionnaire: A patient-reported outcome measure for the quality of life impact of itch. J Invest Dermatol 2020; 140: 986–994. DOI: https://doi.org/10.1016/j.jid.2019.08.452
Haest C, Casaer MP, Daems A, De Vos B, Vermeersch E, Morren MA, et al. Measurement of itching: Validation of the Leuven Itch Scale. Burns 2011; 37: 939–950. DOI: https://doi.org/10.1016/j.burns.2011.04.007
Desai NS, Poindexter GB, Monthrope YM, Bendeck SE, Swerlick RA, Chen SC. A pilot quality-of-life instrument for pruritus. J Am Acad Dermatol 2008; 59: 234–244. DOI: https://doi.org/10.1016/j.jaad.2008.04.006
Frew JW, Martin LK, Nijsten T, Murrell DF. Quality of life evaluation in epidermolysis bullosa (EB) through the development of the QOLEB questionnaire: An EB-specific quality of life instrument. Br J Dermatol 2009; 161: 1323–1330. DOI: https://doi.org/10.1111/j.1365-2133.2009.09347.x
Okata-Karigane U, Pathmarajah P, Gorell ES, Sum K, Yekrang K, Phung M, et al. Evaluation of antipruritic effects of serlopitant, a neurokinin 1 receptor antagonist, in patients with epidermolysis bullosa: A phase 2 randomized controlled trial. J Eur Acad Dermatol Venereol 2025; 39: e215–e217. DOI: https://doi.org/10.1111/jdv.20189
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
